Chronic Kidney Disease Market by Type, Indication, End-User

List of Tables

The Chronic Kidney Disease Market was valued at USD 128.45 billion in 2023, expected to reach USD 136.56 billion in 2024, and is projected to grow at a CAGR of 6.50%, to USD 199.64 billion by 2030.

Chronic Kidney Disease (CKD) refers to a long-term condition characterized by gradual loss of kidney function, affecting millions globally due to factors such as diabetes and hypertension. The market scope includes pharmaceuticals, diagnostics, dialyzers, and renal transplantation, marking a critical necessity in the healthcare sector. CKD management involves early diagnosis, monitoring, treatment adherence, and consulting specialized clinics, addressing both healthcare providers' needs and enhancing patient outcomes. The end-use segmentation primarily focuses on hospitals, diagnostic laboratories, and research institutes, driving market demand through advancements in therapeutic and diagnostic measures. Key growth factors influencing the CKD market include increasing prevalence of diabetes and hypertension, technological advancements in diagnostic and treatment procedures, and supportive governmental policies. Potential opportunities lie in developing personalized medicine and telehealth services to provide continuous patient monitoring. Companies should consider investments in AI-driven diagnostic tools and wearable devices to enhance patient adherence and monitoring, addressing unmet clinical needs effectively. However, market growth faces limitations such as high treatment costs, regulatory challenges, and inadequate awareness among patients about early diagnosis and treatment adherence. Furthermore, the integration of innovative technologies like AI, machine learning, and blockchain could streamline operations, improve patient diagnosis accuracy, and facilitate secure patient data management. Research into nephrology and development of advanced biopharmaceuticals tailored for CKD can also propel business growth. The CKD market is highly dynamic and consumer-centric, demanding constant innovation and adaptation to regulatory and technological changes. Keeping pace with these advancements and focusing on improving patient outcomes through personalized care and digital health solutions can significantly enhance market presence and profitability. In light of these factors, companies should prioritize strategic collaborations and research partnerships to harness emerging technological trends effectively.

KEY MARKET STATISTICS
Base Year [2023]	USD 128.45 billion
Estimated Year [2024]	USD 136.56 billion
Forecast Year [2030]	USD 199.64 billion
CAGR (%)	6.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Kidney Disease Market

The Chronic Kidney Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing global prevalence of chronic kidney disease with the aging population
- Supportive government and regulatory policies aimed at improving healthcare infrastructure
- Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
Market Restraints
- High cost and gap in product standardization across regions
Market Opportunities
- Advancements in treatment and diagnostic technologies and product innovation
- Expansion of telemedicine and remote monitoring technologies
Market Challenges
- Limited commercialization of advanced kidney disease treatments

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Kidney Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Kidney Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Kidney Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Kidney Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Kidney Disease Market

A detailed market share analysis in the Chronic Kidney Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Kidney Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Kidney Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Kidney Disease Market

A strategic analysis of the Chronic Kidney Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Kidney Disease Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allmed Medical Products Co., Ltd., AngioDynamics, Inc., Apotex Inc., Asahi Kasei Corporation, AstraZeneca PLC, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Centessa Pharmaceuticals Limited, DaVita Inc., Dialife SA, Dr. Reddys Laboratories Ltd., Evoqua Water Technologies LLC, Fresenius Medical Care AG, Galapagos NV, Hemoclean Co. Ltd., JMS Co., Ltd., Johnson & Johnson Services, Inc., Medtronic PLC, Merck & Co., Inc., Nikkiso Co., Ltd., Nipro Corporation, Novartis AG, NxStage Medical Inc., Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Rockwell Medical Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Medical Co., Ltd., Trivitron Healthcare, and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Kidney Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Type, market is studied across Diagnosis and Treatment. The Diagnosis is further studied across Blood Tests, Imaging Tests, Kidney Biopsy, and Urine Tests. The Treatment is further studied across Dialysis, Kidney Transplant, and Medication. The Medication is further studied across ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, Erythropoietin Stimulants, Finerenone, Glucagon-like Peptide-1 Receptor Agonists, Insulin, Metformin, Potassium Binders, Sodium-glucose Cotransporter-2 Inhibitors, and Statins.
Based on Indication, market is studied across Chronic Interstitial Nephritis, Diabetic Nephropathy, Glomerulonephritis, Hypertensive Nephropathy, Obstructive Nephropathy, and Polycystic Kidney Disease.
Based on End-User, market is studied across Ambulatory Surgery Centers, Diagnostic Centers & Laboratories, Hospitals & Clinics, and Speciality Treatment Centers.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-99555D550528

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing global prevalence of chronic kidney disease with the aging population
  - 5.1.1.2. Supportive government and regulatory policies aimed at improving healthcare infrastructure
  - 5.1.1.3. Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
- 5.1.2. Restraints
  - 5.1.2.1. High cost and gap in product standardization across regions
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in treatment and diagnostic technologies and product innovation
  - 5.1.3.2. Expansion of telemedicine and remote monitoring technologies
- 5.1.4. Challenges
  - 5.1.4.1. Limited commercialization of advanced kidney disease treatments
5.2. Market Segmentation Analysis
- 5.2.1. Type: Growing need for chronic kidney disease diagnosis solutions to determine the function of the kidneys
- 5.2.2. End-User: Growing accessibility of chronic kidney disease treatments through hospitals & clinics as they offer a broad range of services
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Chronic Kidney Disease Market, by Type

6.1. Introduction
6.2. Diagnosis
- 6.2.1. Blood Tests
- 6.2.2. Imaging Tests
- 6.2.3. Kidney Biopsy
- 6.2.4. Urine Tests
6.3. Treatment
- 6.3.1. Dialysis
- 6.3.2. Kidney Transplant
- 6.3.3. Medication
  - 6.3.3.1. ACE Inhibitors
  - 6.3.3.2. Angiotensin Receptor Blockers
  - 6.3.3.3. Beta Blockers
  - 6.3.3.4. Diuretics
  - 6.3.3.5. Erythropoietin Stimulants
  - 6.3.3.6. Finerenone
  - 6.3.3.7. Glucagon-like Peptide-1 Receptor Agonists
  - 6.3.3.8. Insulin
  - 6.3.3.9. Metformin
  - 6.3.3.10. Potassium Binders
  - 6.3.3.11. Sodium-glucose Cotransporter-2 Inhibitors
  - 6.3.3.12. Statins

7. Chronic Kidney Disease Market, by Indication

7.1. Introduction
7.2. Chronic Interstitial Nephritis
7.3. Diabetic Nephropathy
7.4. Glomerulonephritis
7.5. Hypertensive Nephropathy
7.6. Obstructive Nephropathy
7.7. Polycystic Kidney Disease

8. Chronic Kidney Disease Market, by End-User

8.1. Introduction
8.2. Ambulatory Surgery Centers
8.3. Diagnostic Centers & Laboratories
8.4. Hospitals & Clinics
8.5. Speciality Treatment Centers

9. Americas Chronic Kidney Disease Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Chronic Kidney Disease Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Chronic Kidney Disease Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. FDA Approves Akebia Therapeutics' Vafseo for Treatment of Anemia in CKD Patients
- 12.3.2. FDA Approves Jardiance(R) for Chronic Kidney Disease, Specifies Non-Recommended Uses
- 12.3.3. Signify Health Launches In-Home Kidney Health Evaluations for Medicare Advantage Members
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AbbVie Inc.
2. Allmed Medical Products Co., Ltd.
3. AngioDynamics, Inc.
4. Apotex Inc.
5. Asahi Kasei Corporation
6. AstraZeneca PLC
7. B. Braun SE
8. Baxter International, Inc.
9. Becton, Dickinson and Company
10. Centessa Pharmaceuticals Limited
11. DaVita Inc.
12. Dialife SA
13. Dr. Reddys Laboratories Ltd.
14. Evoqua Water Technologies LLC
15. Fresenius Medical Care AG
16. Galapagos NV
17. Hemoclean Co. Ltd.
18. JMS Co., Ltd.
19. Johnson & Johnson Services, Inc.
20. Medtronic PLC
21. Merck & Co., Inc.
22. Nikkiso Co., Ltd.
23. Nipro Corporation
24. Novartis AG
25. NxStage Medical Inc.
26. Otsuka Pharmaceutical Co., Ltd.
27. Reata Pharmaceuticals Inc.
28. Rockwell Medical Inc.
29. Sanofi S.A.
30. Teva Pharmaceutical Industries Ltd.
31. Toray Medical Co., Ltd.
32. Trivitron Healthcare
33. XORTX Therapeutics Inc.